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Selastase) produced by inflammatory cells. A1AT deficiency
is related to destructive congenital lung parenchymal dis-
ease. Hamrita and coworkers21 reported elevated A1AT
levels in patients with invasive breast cancer.
CYFRA 21-1 (cytokeratin 19 fragment) is reported as be-
ing related to lung cancer. Lai and associates22 reported that
a high serum level of CYFRA 21-1 is related to the ad-
vanced stage and poor prognosis in SCC. Pujol and col-
leagues23 meta-analyzed 2063 patients and reported that
serum concentrations of more than 3.6 ng/mL showed
a lower survival than those with less and the hazard ratio
was 1.88. This study also showed a high serum level of CY-
FRA 21-1 in SCC patients.
IGF-1 is reported to be related to multiple cancers such as
endometrial cancer, breast cancer, ovarian cancer, gastric
cancer, pancreatic cancer, colon cancer, and lung cancer.24
Inasmuch as IGF-1 is a primary mediator of growth hor-
mone, it relates to growth and differentiation of the cell
and to apoptosis.
In summary, we confirmed that our new diagnostic
method using 5 serum biomarkers profiling constructed
by multivariate classification algorithms could distinguish
persons with NSCLC from healthy controls with high accu-
racy. Additional future study of a larger population is nec-
essary to prove the usefulness of this method for early
diagnosis for NSCLC.
We acknowledge Hyun Cho Wi, Yoo Jin Jung, and Yung Min
Kim for their contributions.References
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Dr Daniel Kreisel (St Louis, Mo). Congratulations on a very
nice presentation and a nice study. Thank you for allowing me to
review your manuscript in a timely fashion.
Your study addresses an important issue in thoracic oncology,
the identification of biomarkers, which would ideally allow us to
accurately identify patients with lung cancer in a cost-effective
and practical manner. Your study extends numerous previous stud-
ies that have used profiling of serum markers in an attempt to de-
tect patients who harbor malignancies, including ovarian cancers.
I have 3 questions. You opted to draw the blood from the pa-
tients during surgery, whereas blood from healthy controls was ob-
tained during routine office visits. Inasmuch as inflammatory
responses can affect some of your markers, such as RANTES,
the obvious question is how you account for the confounding fac-
tor of stress associated with surgery or anesthesia in your study
population.
Dr Lee. Thank you, Dr Kreisel, for your very important
question.
Our lung cancer samples were collected during surgery after
general anesthesia. We excluded several biomarkers from the final
modeling to minimize the surgical effect. It is a limitation of our
study.We excluded 3markers: D-dimer, hemoglobin, and interleu-
kin 6. In our additional study of postoperative samples, the scores
calculated with this algorithm had not fallen yet at 3 postoperative
months. That was encouraging, because if the algorithm resultsery c February 2012
Lee et al General Thoracic Surgerymight have been affected owing to surgical effect, the scores
should have fallen by that time. Despite that result, we are planning
to study further and we are collecting new samples for the next-
step studies to compare between the lung cancer group and the be-
nign lung disease group or to compare between the early cancer
group and the advanced cancer group.
Dr Kreisel.How do you suggest your findings should be imple-
mented into clinical practice? Which population would you con-
sider for screening with these biomarkers? Where do you see the
value of the biomarkers compared with screening computed tomo-
graphic scans? I would also like you to comment on the cost aspect
of this assay.
Dr Lee. In this study, about 70%were pathologic stage I. There-
fore, patients with surgically resectable, early-stage lung cancer
were the most targeted population in this study. However, as I
mentioned earlier, the role of this algorithm in the screening of
high-risk patients should be studied further. In as much as com-
puted tomographic screening shows a relatively high false-positive
rate, it may be helpful in that situation. For the price, it may be
lower to test many samples in one plate simultaneously, but it is
difficult to say at this time.
Dr Kreisel. There are extensive standard deviations with this
assay, both in your hands and in multiple other studies. Could
you comment on how reproducible you think this assay would
be if it were to be implemented in the clinical practice?
Dr Lee. Reproducibility is a very important and very difficult
issue in molecular biology. We also considered and kept someThe Journal of Thoracic and Casamples for final validation instead of entering them into the mod-
eling procedure, and we used 4 analytical methods to overcome,
but we know it is not enough. To generalize this result to lung can-
cer, a further larger study should be done, including a randomized
clinical trial. I think that a long process should be done.
Dr David H. Harpole, Jr (Durham, NC). This is a very nice
study.
My only comment is that we and others for many years have
been looking at serum markers predictive of lung cancer. You cor-
rectly state in your last conclusion that there are probably hundreds
of articles in the literature on serum markers that can separate nor-
mal controls from lung cancer patients, but when one takes a group
of patients with suspicious lung nodules who are smokers, most of
them go away, because, frankly, the differential of those patients
tends to be closer. That is an important point.
Second, the value of the beads is that they allow you to look si-
multaneously at a lot of the markers, and you have done some el-
egant modeling to reduce the number of markers. However, the
problem with that is that when we are looking at ADC and SCC,
they can be different. I think you have a good technology here.
You may want to remodel this, frankly, with all of your markers,
so that when you are looking at it with smokers, you may see dif-
ferent ones fall in and out depending on the patients, and it may
prove it to be more predictive. That is the real power of this tech-
nology—allowing you to see 30 markers at once.
Dr Lee. We considered the clinical practice. We did use just
a number of biomarkers. That is a good comment.rdiovascular Surgery c Volume 143, Number 2 427
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